Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Revenue (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Revenue for 12 consecutive years, with $12.7 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 64.85% to $12.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.2 million through Dec 2025, up 59.81% year-over-year, with the annual reading at $42.2 million for FY2025, 59.81% up from the prior year.
  • Revenue hit $12.7 million in Q4 2025 for Coherus Oncology, up from $11.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $91.5 million in Q4 2023 to a low of $2.3 million in Q1 2024.
  • Historically, Revenue has averaged $43.2 million across 5 years, with a median of $45.4 million in 2022.
  • Biggest five-year swings in Revenue: crashed 92.88% in 2024 and later surged 229.25% in 2025.
  • Year by year, Revenue stood at $73.4 million in 2021, then plummeted by 38.19% to $45.4 million in 2022, then skyrocketed by 101.81% to $91.5 million in 2023, then tumbled by 91.55% to $7.7 million in 2024, then surged by 64.85% to $12.7 million in 2025.
  • Business Quant data shows Revenue for CHRS at $12.7 million in Q4 2025, $11.6 million in Q3 2025, and $10.3 million in Q2 2025.